NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

WithdrawnPhase 4

Sponsor: Juan A. Arnaiz

Conditions: Patient Compliance, Antiretroviral Therapy Intolerance

Interventions: elvitegravir/cobicistat/emtricitabine/tenofovir, Darunavir, abacavir/lamivudine, Ritonavir, Lamivudine

The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* 1-negative pregnancy test in women of childbearing age
* 2- stable HIV-1 infection clinically and not take antiretroviral therapy
* 3- viral load HIV \<100,000 copies
* 4- CD4 cells \>100 cels/mm3
* 5- Glomerular filtration \>70mlmin
* 6- have a negative HLA B5701
* 7-.patients should have given informed written consent
* 8- in the opinion of the investigator, be able to follow the design of the Protocol visits

Exclusion Criteria:

* 1-. Patients who had virologic failure with any antiretroviral therapy
* 2- evidence of prior mutations of the study drugs
* 3- use of any anti-retroviral treatment in the 6 months prior to the entry of the study
* 4- contraindication to the drugs study
* 5- any condition that does not allow to ensure the correct compliance to the study
* 6- uncontrolled previous psychiatric illness
* 7- Current or active addiction or alcoholism